Presentation is loading. Please wait.

Presentation is loading. Please wait.

Safety and Efficacy of Combination Therapy of Interferon- Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms.

Similar presentations


Presentation on theme: "Safety and Efficacy of Combination Therapy of Interferon- Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms."— Presentation transcript:

1 Safety and Efficacy of Combination Therapy of Interferon- Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study by Stine Ulrik Mikkelsen, Lasse Kjær, Vibe Skov, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Daniel El Fassi, Torben A Kruse, Thomas Stauffer Larsen, Torben Mourits-Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, and Hans Carl Hasselbalch Blood Volume 126(23):824-824 December 3, 2015 ©2015 by American Society of Hematology

2 Stine Ulrik Mikkelsen et al. Blood 2015;126:824 ©2015 by American Society of Hematology

3 Stine Ulrik Mikkelsen et al. Blood 2015;126:824 ©2015 by American Society of Hematology

4 Stine Ulrik Mikkelsen et al. Blood 2015;126:824 ©2015 by American Society of Hematology


Download ppt "Safety and Efficacy of Combination Therapy of Interferon- Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms."

Similar presentations


Ads by Google